
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc's current enterprise value of approximately $430 million suggests a significant potential for growth, with estimates indicating an 8-10x upside in share price if their collaboration with Novoproves proves successful. The company's management expresses confidence in executing Phase 1 trials more efficiently for their candidate SEP-786, leveraging their past experience to potentially yield better results. Moreover, if SEP-631 can match the efficacy of Xolair, a drug with nearly $3.9 billion in sales, it could reach blockbuster status, particularly due to its anticipated enhanced convenience profile.
Bears say
Septerna Inc faces several significant risks that contribute to a negative outlook for its stock, including potential delays in clinical development for its pipeline candidates such as SEP-631 and the possibility of setbacks in ongoing clinical trials. Additionally, the company's partnership with Novo Nordisk poses further uncertainties, while the risk of not securing regulatory approvals for key candidates and lower-than-expected market penetration could hinder future revenue generation. Furthermore, a recent transaction in the obesity sector highlights a potential valuation gap, which may raise concerns among investors regarding Septerna's financial prospects.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares